Avenue Therapeutics, a New York-based specialty pharmaceutical firm, is currently focused on developing and bringing revolutionary products to market for use in the acute/intensive care hospital setting. The company's lead product candidate is intravenous Tramadol, a synthetic dual-acting opioid designed to treat post-operative acute pain. Currently in Phase III clinical trials, Avenue Therapeutics is poised to make a significant impact in the field of pain management. The company, which was founded in 2015, is at the forefront of cutting-edge research in the pharmaceutical industry.